XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 24.91

-1.7%

Dec 18 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JOEBT1 who wrote (8193)	1/5/1999 1:30:00 PM
From: aknahow	Read Replies (2) of 17367

I can't calculate it. Cacaito can if he sees your post and has the time. The problem with the data in the article you saw, which is similar to the one I posted yesterday, is that one is never sure they are not mixing in meningitis cases with meningococcemia cases, regardless of what the article refers to. Second if trials in the U.K. have resulted in treating 150 patients with Neuprex the data would be influenced if Neuprex worked. Agreed it would not reduce the mortality rate from 20 to 10% And I do agree that early treatment in the U.K. is supposed to have reduced the death rate, and yes I feel that this makes it logical for XOMA to want to obtain more patients to assure statistical significance. BTW looks like volume will be well above a million shares today.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next